TIGAR knockdown could notably inhibit IR-induced Trx1 nuclear translocation both in vitro and in vivo, and prolonged the survival time of nude mice bearing TrxR1-overexpressing gliomas, which supported the idea that TIGAR abrogation might be a possible adjunctive therapeutic strategy against TrxR1-overexpressing glial tumours. The gene discussed is TXN; the disease is central nervous system cancer.